Table 2

Characteristics of the 20 patients with tuberculosis following ICI exposure

Patient numberAge, yearsSexCancer typeOther comorbiditiesType of ICITotal ICI cycles receivedInterval* (months)Type of TBConcomitant corticosteroidConcomitant immunosuppressant
173MaleLung cancerNoneNivolumab55.7PulmonaryNoNo
280MaleLung cancerHypertension and chronic lung diseaseNivolumab11.3PulmonaryNoNo
365MaleLung cancerChronic lung diseaseNivolumab81.7MiliaryNoNo
482MaleLung cancerChronic lung diseasePembrolizumab61.3PulmonaryNoNo
574FemaleLung cancerHypertension, diabetes and chronic kidney diseasePembrolizumab20.4MeningitisYesNo
681FemaleMelanomaHypertension and chronic lung diseasePembrolizumab20.7PulmonaryNoNo
765MaleLung cancerNonePembrolizumab32.8VertebraYesNo
844FemaleLung cancerHypertensionNivolumab21.5PulmonaryNoNo
961MaleLung cancerChronic lung diseasePembrolizumab74.7PericarditisNoNo
1064MaleLung cancerHypertension and diabetesPembrolizumab75.3PulmonaryYesNo
1158MaleLung cancerNonePembrolizumab22.3PulmonaryNoNo
1259MaleLung cancerHypertension and chronic lung diseasePembrolizumab10.9PulmonaryYesNo
1371MaleLung cancerHypertension and chronic lung diseaseNivolumab20.6PulmonaryNoNo
1453MaleLung cancerChronic lung diseaseNivolumab107.5PulmonaryYesNo
1554MaleLung cancerDiabetes and chronic lung diseasePembrolizumab22.8PulmonaryNoNo
1679MaleLung cancerChronic lung diseasePembrolizumab32.0PulmonaryYesNo
1767FemaleLung cancerHypertension and diabetesNivolumab1016.5PulmonaryYesNo
1878MaleLung cancerChronic lung diseasePembrolizumab1013.6PulmonaryNoYes
1961MaleLung cancerHypertension, diabetes and chronic lung diseasePembrolizumab20.6PulmonaryYesNo
2083MaleLung cancerChronic lung diseaseNivolumab109.1PulmonaryNoNo
  • *Interval from the first administration of the ICI to the development of TB

  • ICI, immune checkpoint inhibitor; TB, tuberculosis.